Priced for a smaller company: management is quietly telling investors the business has already outgrown what the numbers
The model's full reasoning — Q2 2023 call → NOWe need to determine if management conveys that outsiders are currently underweighting something the company has already done, and points to a concrete, already-completed or already-operating piece of the business whose contribution is still largely ahead of reported results. Let's analyze the transcript. Rich Gelfond and Natasha Fernandes speak. They discuss strong Q2 results, signings, installations, box office, etc. They mention Oppenheimer's success, local language films, network growth, SSIMWAVE, IMAX China acquisition, etc. Key points: They talk about the paradigm shift to IMAX, market share gains, signings up, installations ramping. They mention that they are on track for significant growth. They also mention the IMAX China acquisition proposal. They talk about SSIMWAVE as a new technology with potential. Do they convey that outsiders are underweighting something already done? They say "we believe our performance and broader market trends demonstrate a paradigm shift in cinema with IMAX getting increasing market share." They also say "we are confident in our ability to build on our momentum." They don't explicitly say that analysts or investors are underweighting something. They do mention that they have a strong brand and technology, and that they are expanding. But is there a recognition gap? They say "we remain on track to deliver significant growth in system signings, installations, global box office and adjusted EBITDA for the full year." That's forward-looking. They also mention "we recently took a significant strategic step with our proposal to acquire full ownership of our IMAX China subsidiary." That's a concrete action, but it's a proposal, not yet completed. They also mention "we announced an agreement to sell worldwide rights to our forthcoming documentary, the Blue Angels to Amazon Studios." That's a deal, but the film is forthcoming. They talk about SSIMWAVE: "We continue to refine our go-to-market strategy with SSIMWAVE and we're seeing a positive response with streamings encouraged by our efforts to champion quality in that space." That's still early. Do they point to something already built and operating whose contribution is still ahead? They mention the 84 signings year-to-date, which is more than all of last year.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| KEY | KeyCorp | Q3 2022 | 2022-10-20 | B+ |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
PRPH · Q1 2023 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES The transcript shows management explicitly framing the current market view as mismatched with the company's actual position: "Anybody that's focused on us for earnings, you invested or are following the wrong company," "we're not an earnings story this year," and "focus less on revenues and earnings. This is a transition year." They repeatedly contrast this with the multi-billion-dollar assets already built and operating, whose contributions are still ramping or largely ahead. Concrete already-real items with meaningful payoff still ahead include: - The manufacturing facility (already at capacity, running nearly 100% YoY growth, with $25M revenue target for 2024 constrained only by capacity expansion this year; estimated $70M valuation next year plus $40M working capital and tens of millions in equipment). - Nebula Genomics (already generating >100% YoY revenue growth via direct-to-consumer sales; in-house whole-genome processing and B2B ramp expected in H2 202 3, particularly Q4, after validations complete in a couple of months).
KEY · Q3 2022 → YESThe question is: Does management convey that OUTSIDERS ARE CURRENTLY UNDERWEIGHTING SOMETHING THE COMPANY HAS ALREADY DONE — and does management answer that gap by pointing to at least one CONCRETE, A...YES Management repeatedly frames its interest-rate-risk positioning as something that “sets Key apart” and creates “unique and significant upside” that is not yet reflected in the market’s view of the company. Chris Gorman states that the $1.2 billion annualized benefit from re-pricing existing short-term Treasuries and swaps “ even in the event that rates remain at current levels” will arrive over the next two years, and Don Kimble confirms the same mechanics and timing. The $9 billion in short-term Treasuries and $26 billion in swaps are already on the balance sheet; the contribution is simply not yet in the reported results.
KIM · Q2 2018 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES Management explicitly frames the public-private pricing disconnect as a gap in how the company is valued versus its actual assets and execution. They point to the already-completed Toys "R" Us liquidation process (22 boxes resolved into OpCo and PropCo leases, with seven OpCo leases already signed and seven PropCo under 18-24 month resolution) as a concrete, already-real item whose rent contribution is still largely ahead in the reported results, with the 70-80 bps impact on occupancy and same-site NOI expected to be recaptured in Q3 and beyond.